New Zealand markets closed

IPA Jan 2024 2.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.00000.0000 (0.00%)
As of 02:13PM EST. Market open.
Full screen
Previous close3.0000
Open3.0000
Bid0.0000
Ask0.0000
Strike2.50
Expiry date2024-01-19
Day's range3.0000 - 3.0000
Contract rangeN/A
Volume10
Open interest10
  • Business Wire

    IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

    VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA, November 30, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology c

  • Business Wire

    ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

    VICTORIA, British Columbia, November 22, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV"). Accordingly, it is anticipated that, effective as at the close of trading on Friday, November 25, 2022, IPA’s common shares will no longer be listed and posted for trading on the TSXV.

  • Business Wire

    IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

    VICTORIA, British Columbia, October 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), today announced that its subsidiary, Talem Therapeutics LLC ("Talem"), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated. The agreement builds upon Talem’s extensive antibody development expertise and its access to LENSai™ in silico software technology to further the development and commerciali